Generalized Convulsions in a Patient Receiving Ultrashort-Acting Beta-Blocker Infusion

1988 ◽  
Vol 22 (6) ◽  
pp. 484-485 ◽  
Author(s):  
Gopal Das ◽  
Janine C. Ferris
Keyword(s):  
Heart Disease ◽  
Beta Blocker ◽  
Blocking Agent ◽  
Literature Survey ◽  
Receptor Blocking ◽  
Blocking Agents ◽  
Beta Receptor ◽  
Generalized Seizures ◽  
Beta Blocking ◽  
Therapeutic Doses

Beta-receptor blocking agents are commonly used to treat patients with heart disease, and generalized seizures due to therapy with these agents are rare. All reported cases of seizures due to beta blocking agents have occurred only in those subjects who ingested large doses of the drugs. We observed generalized convulsions in a patient who was receiving therapeutic doses of an ultrashort-acting beta-blocking agent (esmolol hydrochloride) intravenously. A literature survey and possible mechanisms by which these agents induce seizures are presented.

Claims for cordilox

1967 ◽  
Vol 5 (22) ◽  
pp. 85-86
Keyword(s):  
Angina Pectoris ◽  
Blocking Agent ◽  
Receptor Blockade ◽  
Clinical Use ◽  
Sympathetic Stimulation ◽  
Blocking Agents ◽  
Beta Receptor ◽  
Beta Blocking ◽  
Beta Receptor Blockade

Verapamil (Cordilox - Pfizer; iproveratril*), described by the manufacturers as a mild beta-blocking agent, is promoted as an important new compound for the long-term control of angina pectoris.1 It is claimed that, unlike other beta-blocking agents which reduce the response of the heart to sympathetic stimulation, verapamil induces neither coronary vasoconstriction nor broncho-spasm and is less likely to provoke low-output cardiac failure. These unwanted effects are an unavoidable consequence of intense beta receptor blockade, and (although the manufacturers attribute the advantages to a direct relaxation of plain muscle) their absence suggests that the action of verapamil may depend not on beta receptor blockade but on other mechanisms. The claims for verapamil of advantages over potent beta-blocking agents are clearly aimed at propranolol (Inderal - ICI), the only one available for clinical use. We discussed propranolol in 1965.1

scholarly journals The Myocardial Depressant Effect of Beta-Receptor Blocking Agents

1974 ◽  
Vol 35 (2) ◽  
pp. 272-280 ◽  
Author(s):  
CHANG-SENG LIANG ◽  
WILLIAM B. HOOD
Keyword(s):  
Depressant Effect ◽  
Receptor Blocking ◽  
Blocking Agents ◽  
Beta Receptor

scholarly journals EFFECT OF A NEW BETA-RECEPTOR BLOCKING AGENT, BFE-60 ON CARDIOVASCULAR SYSTEM

1973 ◽  
Vol 23 ◽  
pp. 35
Author(s):  
Yoichi Maruyama ◽  
Takafumi Ishihara ◽  
Ichiva Hiraki ◽  
Masayoshi Nozaki ◽  
Fumio Takenaka
Keyword(s):  
Cardiovascular System ◽  
Blocking Agent ◽  
Receptor Blocking ◽  
Beta Receptor
Sign in / Sign up

Export Citation Format

Share Document